Paper Details

  1. Home
  2. Paper Details

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

Author: BergamaschiMateus M, ChagasMarcos Hortes N, CrippaJosé Alexandre S, HallakJaime E C, Pena-PereiraMárcio Alexandre, SobreiraEmmanuelle T, TeixeiraAntonio Lucio, TumasVitor, ZuardiAntonio W, dos SantosAntonio Carlos

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 21 patients with Parkinson's disease (PD) found that cannabidiol (CBD) may improve quality of life measures in PD patients with no psychiatric comorbidities. However, further studies with larger samples are needed to confirm this finding.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Parkinson's disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target. METHODS: From a sample of 119 patien...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/0269881114550355

データ提供：米国国立医学図書館（NLM）

Cannabidiol: A Potential Oasis in the Parkinson's Desert

The [Parkinson's disease (PD)] desert is a challenging one, marked by a progressive degeneration of dopaminergic neurons. This study explores the potential of cannabidiol (CBD) as a therapeutic agent for PD, examining its effects on motor symptoms, quality of life, and potential neuroprotective mechanisms. The researchers conducted a double-blind trial, comparing the effects of placebo, CBD 75 mg/day, and CBD 300 mg/day in patients with PD. While the study didn't find significant differences in motor symptom scores or neuroprotective markers, it did reveal a potential improvement in quality of life measures for those receiving CBD 300 mg/day.

Quality of Life: A Crucial Element in the PD Desert

The study highlights the importance of improving quality of life for patients with PD, suggesting that CBD may offer a potential avenue for achieving this. It's like discovering a hidden oasis in the harsh desert, providing a respite from the challenges of PD and offering a chance to experience a better quality of life. While further research is needed, the study's findings offer hope for finding new ways to support those living with this debilitating condition.

Exploring New Paths in the PD Desert

This research underscores the need for continued exploration of novel therapeutic approaches for PD, aiming to address both motor symptoms and quality of life. It's like searching for new trails and pathways through the PD desert, seeking out potential solutions to improve the lives of those living with this condition. The study's findings, while promising, require further investigation to fully understand the potential benefits of CBD for PD patients.

Dr. Camel's Conclusion

This study offers a glimpse of hope for patients with PD, suggesting that CBD may have the potential to improve quality of life. It's like finding a spring of fresh water in the middle of a dry desert, offering a renewed sense of well-being and hope for the future.

Date :
  1. Date Completed 2015-09-18
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

25237116

DOI: Digital Object Identifier

10.1177/0269881114550355

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.